Company Description: Emerson Electric Co. designs and supplies product technology, and delivers engineering services and solutions to a wide range of industrial, commercial and consumer markets around the world.
Fair Value: In calculating fair value, I consider the NPV MMA Differential Fair Value along with these four calculations of fair value, see page 2 of the linked PDF for a detailed description:
1. Avg. High Yield Price
2. 20-Year DCF Price
3. Avg. P/E Price
4. Graham Number
EMR is trading at a premium to all four valuations above. When also considering the NPV MMA Differential, the stock is trading at a 7.3% premium to its calculated fair value of $51.99. EMR did not earn any Stars in this section.
Dividend Analytical Data: In this section there are three possible Stars and three key metrics, see page 2 of the linked PDF for a detailed description:
1. Free Cash Flow Payout
2. Debt To Total Capital
3. Key Metrics
4. Dividend Growth Rate
5. Years of Div. Growth
6. Rolling 4-yr Div. > 15%
EMR earned two Stars in this section for 1.) and 3.) above. A Star was earned since the Free Cash Flow payout ratio was less than 60% and there were no negative Free Cash Flows over the last 10 years. EMR earned a Star for having an acceptable score in at least two of the four Key Metrics measured. The company has paid a cash dividend to shareholders every year since 1947 and has increased its dividend payments for 60 consecutive years.
Dividend Income vs. MMA: Why would you assume the equity risk and invest in a dividend stock if you could earn a better return in a much less risky money market account (MMA) or Treasury bond? This section compares the earning ability of this stock with a high yield MMA. Two items are considered in this section, see page 2 of the linked PDF for a detailed description:
1. NPV MMA Diff.
2. Years to > MMA
EMR earned a Star in this section for its NPV MMA Diff. of the $532. This amount is in excess of the $500 target I look for in a stock that has increased dividends as long as EMR has. The stock's current yield of 3.4% exceeds the 1.81% estimated 20-year average MMA rate.
Peers: The company's peer group includes: Espey Manufacturing & Electronics Corp. (ESP) with a 3.8% yield, ABB Ltd. (ABB) with a 3.7% yield and Regal Beloit Corporation (RBC) with a 1.6% yield.
Conclusion: EMR did not earn any Stars in the Fair Value section, earned two Stars in the Dividend Analytical Data section and earned one Star in the Dividend Income vs. MMA section for a total of three Stars. This quantitatively ranks EMR as a 3-Star Hold stock.
Using my D4L-PreScreen.xls model, I determined the share price would need to increase to $57.35 before EMR's NPV MMA Differential decreased to the $500 minimum that I look for in a stock with 60 years of consecutive dividend increases. At that price the stock would yield 3.3%.
Resetting the D4L-PreScreen.xls model and solving for the dividend growth rate needed to generate the target $500 NPV MMA Differential, the calculated rate is 0.8%. This dividend growth rate is lower than the 1.1% used in this analysis, thus providing a margin of safety. EMR has a risk rating of 1.25 which classifies it as a Low risk stock.
EMR holds a broad portfolio of industrial businesses with a strong competitive positions. The company has a reputation for providing consistent returns to its investors. The company's advantages include globally branded platforms, new products in the pipeline. Its free cash flow payout of 56% (down from 69%) is within my acceptable level, while debt to total capital of 49% (down from 50%) is slightly above my preferred maximum. The stock is currently trading above my calculated fair value price of $51.99, so I will wait for a more opportune time before significantly adding to my position.
Disclaimer: Material presented here is for informational purposes only. The above quantitative stock analysis, including the Star rating, is mechanically calculated and is based on historical information. The analysis assumes the stock will perform in the future as it has in the past. This is generally never true. Before buying or selling any stock you should do your own research and reach your own conclusion. See my Disclaimer for more information.
Full Disclosure: At the time of this writing, I was long in EMR (2.5% of my Dividend Growth Portfolio). See a list of all my Dividend Growth Portfolio holdings here.
Related Articles:
- Kimberly-Clark Co. (KMB) Dividend Stock Analysis
- Illinois Tool Works Inc. (ITW) Dividend Stock Analysis
- Wells Fargo & Company (WFC) Dividend Stock Analysis
- Pepsico, Inc. (PEP) Dividend Stock Analysis
- ConocoPhillips Co. (COP) Dividend Stock Analysis
- More Stock Analysis
Tags: EMR, ESP, ABB, RBC,
